Search results for "INHALATION"

showing 10 items of 326 documents

Effect of beclomethasone dipropionate on the bronchial responsiveness to propranolol in asthmatics.

1990

The effect of four weeks of treatment with beclomethasone dipropionate (BDP, 500 micrograms twice daily) on the bronchial responsiveness to propranolol was examined in 16 patients with mild asthma in a placebo-controlled, double-blind crossover study. Propranolol was inhaled in doubling concentrations and the results were expressed as the cumulative dose producing a 20 percent fall in FEV1 (PC20). After four weeks of treatment with BDP, the mean FEV1 increased from 82.0 percent predicted to 88.1 percent predicted. The difference was significant (p less than 0.001). Treatment with BDP did not significantly change the responsiveness to propranolol, the geometric mean PC20 being 3.17 mg/ml bef…

Pulmonary and Respiratory MedicineAdultMaleTime FactorsMild asthmaPropranololCritical Care and Intensive Care MedicineBronchial Provocation TestsRandom AllocationDouble-Blind MethodForced Expiratory VolumeAdministration InhalationmedicineAsthmatic patientHumansAsthmaBronchial SpasmCumulative dosebusiness.industryRespiratory diseaseBeclomethasonerespiratory systemmedicine.diseaseCrossover studyPropranololAsthmaAnesthesiaBronchoconstrictionFemalemedicine.symptomCardiology and Cardiovascular Medicinebusinessmedicine.drugChest
researchProduct

Feasibility of functional magnetic resonance lung imaging in Australia with long distance transport of hyperpolarized helium from Germany.

2008

MRI of the lung using hyperpolarized helium as an inhaled contrast agent has important research applications and clinical potential. Owing to the limited availability of hyperpolarized helium, this type of imaging has not been performed in the human lung outside of North America or Europe. The objective of this study was to test the feasibility of imaging human lungs in Australia using hyperpolarized helium gas imported from Germany.A Bruker 2-Tesla whole-body magnetic resonance scanner located in Brisbane, Australia was adapted with a helium-3 radiofrequency transceiver coil. Helium-3 was hyperpolarized to 72% in Mainz, Germany and airfreighted to Brisbane. The time taken for the journey w…

Pulmonary and Respiratory MedicineAdultMalegenetic structuresContrast MediaHeliumHuman lungIsotopesGermanyLung imagingAdministration InhalationmedicineHumansmedicine.diagnostic_testbusiness.industryAustraliaMagnetic resonance imagingrespiratory systemDiagnostic ServicesMagnetic Resonance Imagingrespiratory tract diseasesHyperpolarized heliumImportant researchmedicine.anatomical_structureFeasibility StudiesNuclear medicinebusinessAviationRespirology (Carlton, Vic.)
researchProduct

Efficacy of a fixed combination of ciclesonide and formoterol: the EXCITED-study.

2011

SummaryRecommended treatment for moderate to severe asthma is the combination of an inhaled corticosteroid and a long-acting beta2-agonist. The present study was designed to evaluate the efficacy of a newly developed fixed combination of ciclesonide and formoterol in comparison to the marketed fixed combination of fluticasone and salmeterol in patients with moderate asthma.This was a phase II, multi-centre, randomized, parallel-group, double-blind, double-dummy study. After a 2-week run-in period, 160 patients with moderate asthma were randomized to a 6-week treatment with ciclesonide/formoterol 320/9 μg bid (CIC/F) or fluticasone propionate/salmeterol 250/50 μg bid (FP/S), both delivered a…

Pulmonary and Respiratory MedicineAdultMalemedicine.medical_specialtyAdolescentUrologyCiclesonideCiclesonideFluticasone propionatechemistry.chemical_compoundYoung AdultDouble-Blind Methodimmune system diseasesPregnenedionesForced Expiratory VolumeFormoterol FumarateGermanyAdministration InhalationmedicineHumansFixed combinationAlbuterolFormoterolAnti-Asthmatic AgentsChildGlucocorticoidsFluticasoneAgedFluticasone-Salmeterol Drug Combinationbusiness.industryrespiratory systemMiddle AgedAsthmaFluticasone-Salmeterol Drug Combinationrespiratory tract diseasesBronchodilator AgentsAndrostadienesDrug CombinationsTreatment OutcomeTolerabilitychemistryEthanolaminesAustriaFormoterol FumarateFemaleSalmeterolFormoterolbusinessmedicine.drugRespiratory medicine
researchProduct

Anti-muscarinic drugs as preventive treatment of exercise-induced bronchoconstriction (EIB) in children and adults.

2020

Regular physical activity is strongly recommended to prevent chronic respiratory diseases, including asthma. On the other hand, vigorous physical training may trigger airway symptoms and bronchoconstriction. The transient airway narrowing occurring because of exercise is named exercise-induced bronchoconstriction (EIB). Despite management according to guidelines, a significant proportion of patients experiences uncontrolled EIB, which thus represents a relevant unmet medical need. In particular, although prevention and treatment of EIB are effectively based on the use of beta-2 bronchodilator drugs, high heterogeneity in individual responses has been reported. Furthermore, even though beta-…

Pulmonary and Respiratory MedicineAdultMalemedicine.medical_specialtyAdolescentmedicine.drug_classBronchoconstrictionMuscarinic Antagonists03 medical and health sciencesYoung Adult0302 clinical medicineBronchodilatorAdministration InhalationRespiratory HypersensitivityMedicineAdrenergic DrugsHumans030212 general & internal medicineIntensive care medicineAdverse effectChildAsthmabusiness.industrymedicine.diseaseResponse VariabilityExercise-induced bronchoconstrictionBronchodilator AgentsAnti-muscarinic030228 respiratory systemDelayed-Action PreparationsSettore MED/11 - MALATTIE DELL'APPARATO CARDIOVASCOLAREAnti muscarinicSystematic reviewBronchoconstrictionFemalemedicine.symptomAirwaybusinesshuman activitiesPhysical Conditioning HumanRespiratory medicine
researchProduct

The bronchodilatory effect of deep inspiration diminishes with aging

2004

AbstractDeep inspirations have the ability to dilate constricted airways. The impairment of this function has been associated with the occurrence of asthmatic symptoms. We evaluated whether the bronchodilatory effect of deep inspiration (DI) is affected by aging. We tested 25 healthy subjects (median age: 54 yrs, range: 25–83 yrs). Single dose methacholine (Mch) provocations were performed in the absence of DI, which induced at least 15% reduction in inspiratory vital capacity (IVC) from baseline. The post-Mch IVC measurement was followed by 4 DIs and by another IVC (post-DI IVC). The fractional difference between post-DI IVC and post-Mch IVC represented the % bronchodilation by DI. The % b…

Pulmonary and Respiratory MedicineAdultMalemedicine.medical_specialtyAgingVital CapacityBronchiSettore MED/10 - Malattie Dell'Apparato RespiratorioBronchoconstrictor AgentsDeep inspirationInternal medicineBronchodilationRespirationmedicineHumansMethacholine ChlorideAgedAged 80 and overMethacholinebusiness.industrylung function elderlyHealthy subjectsMiddle AgedSurgeryBronchodilatationInhalationAgeingCardiologycardiovascular systemMethacholineFemaleBronchodilationbusinessmedicine.drugInspiratory vital capacityRespiratory Medicine
researchProduct

A dose-ranging study of indacaterol in obstructive airways disease, with a tiotropium comparison.

2008

This dose-ranging study assessed the bronchodilator efficacy and tolerability of indacaterol, a novel once-daily inhaled beta2-agonist, in subjects clinically diagnosed with COPD. Comparative data with tiotropium were collected. In the double-blind, core period of the study, 635 subjects with COPD (prebronchodilator FEV(1)40% of predicted and > or =1.0L; FEV1/FVC <70%) were randomized to receive indacaterol 50, 100, 200 or 400microg or placebo via multi-dose dry powder inhaler, or indacaterol 400microg via single-dose dry powder inhaler, once daily for 7 days. After completing double-blind treatment and washout, a subset of subjects from each treatment group entered an open-label extension …

Pulmonary and Respiratory MedicineAdultMalemedicine.medical_specialtyEfficacymedicine.drug_classScopolamine DerivativesQuinolonesFEV1/FVC ratioPulmonary Disease Chronic ObstructiveDouble-Blind MethodBronchodilatorForced Expiratory VolumeAdministration InhalationCOPDMedicineHumansTiotropium BromideIndacaterolAgedCOPDDose-Response Relationship Drugbusiness.industryTiotropiumTiotropium bromideMiddle AgedDose-ranging studymedicine.diseaseDry-powder inhalerrespiratory tract diseasesSurgeryBronchodilator AgentsTreatment OutcomeTolerabilityDoseAnesthesiaIndansIndacaterolFemaleSafetybusinessmedicine.drugRespiratory medicine
researchProduct

Efficacy of once-daily tiotropium Respimat in adults with asthma at GINA Steps 2-5.

2020

Tiotropium Respimat is an efficacious add-on to maintenance treatment in patients with symptomatic asthma. Currently, the Global Initiative for Asthma (GINA) strategy recommends tiotropium for patients at Steps 4–5. To assess the clinical benefits of tiotropium Respimat across asthma severities, GINA Steps 2–5, a post hoc analysis of five double-blind trials (12–48-weeks; patients aged 18–75 years) investigated the effect of tiotropium Respimat, 5 μg or 2.5 μg, versus placebo, on peak forced expiratory volume in 1 s (FEV1) within 3 h post-dose (FEV1(0–3h)) response, and Asthma Control Questionnaire-7 (ACQ-7) responder rate. GINA step grouping was based on patients’ background treatment regi…

Pulmonary and Respiratory MedicineAdultMalemedicine.medical_specialtyRespimatAdolescentINHALED CORTICOSTEROIDSPlaceboSALMETEROLDouble-Blind MethodADD-ONStatistical significanceInternal medicineAsthma controlPost-hoc analysisAdministration InhalationmedicineHumansPharmacology (medical)Tiotropium BromideCOMBINATIONDisease severityLungAsthmaAgedbusiness.industryTiotropiumBiochemistry (medical)IMPROVES LUNG-FUNCTIONOdds ratioMiddle Agedmedicine.diseaseGINAConfidence intervalLung functionAsthmarespiratory tract diseasesBronchodilator AgentsTreatment OutcomeSAFETYFemaleSalmeterolbusinessmedicine.drugSYMPTOMATIC ASTHMAPulmonary pharmacologytherapeutics
researchProduct

Inhaled iloprost to control residual pulmonary hypertension following pulmonary endarterectomy.

2005

Objective: Pulmonary endarterectomy (PEA) is the standard therapy for patients with chronic thromboembolic pulmonary hypertension (CTEPH). In the immediate postoperative period, persistent pulmonary hypertension increases the risk of acute respiratory or right heart failure. In pulmonary arterial hypertension, prostanoid inhalation has been found to improve pulmonary hemodynamics, right ventricular function, gas exchange, and clinical outcome. We report the results of a double-blinded randomized trial with the aerosolized prostacyclin analogue iloprost in patients with residual pulmonary hypertension after PEA. Methods: Twenty-two patients (age, 55 � 13 years; 8 females; propofol- and sufen…

Pulmonary and Respiratory MedicineAdultMalemedicine.medical_specialtymedicine.medical_treatmentHypertension PulmonaryPartial PressureVasodilator AgentsEndarterectomyPulmonary ArteryDouble-Blind MethodInternal medicineAdministration InhalationmedicineHumansIloprostProspective StudiesEndarterectomyAgedMechanical ventilationLungbusiness.industryPulmonary Gas ExchangeRespiratory diseaseHemodynamicsGeneral MedicineCarbon DioxideMiddle Agedmedicine.diseasePulmonary hypertensionOxygenmedicine.anatomical_structureTreatment OutcomeAnesthesiaCirculatory systemVascular resistanceCardiologySurgeryFemaleCardiology and Cardiovascular MedicinebusinessIloprostmedicine.drugEuropean journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery
researchProduct

Inhaled iloprost in patients with chronic thromboembolic pulmonary hypertension: effects before and after pulmonary thromboendarterectomy.

2003

Abstract Background In primary pulmonary hypertension, aerosolized prostanoids selectively reduce pulmonary vascular resistance and improve right ventricular function. In this study, hemodynamic effects of inhaled iloprost, a stable prostacyclin analogue, were evaluated in patients with chronic thromboembolic pulmonary hypertension (CTEPH) before and early after pulmonary thromboendarterctomy (PTE). Methods Ten patients (mean age 49 years old [32 to 70 years old], New York Heart Association functional class III and IV) received a dose of 33 μg aerosolized iloprost immediately before surgery (T1), after intensive care unit admission (T2), and 12-hours postoperatively (T3). Effects on pulmona…

Pulmonary and Respiratory MedicineAdultMalemedicine.medical_treatmentHypertension PulmonaryVasodilator AgentsHemodynamicsEndarterectomymedicine.arteryAdministration InhalationPreoperative CaremedicineHumansIloprostPostoperative PeriodEndarterectomyAgedPulmonary thromboendarterectomybusiness.industryRespiratory diseaseMiddle Agedmedicine.diseasePulmonary hypertensionmedicine.anatomical_structureAnesthesiaPulmonary arteryChronic DiseaseVascular resistanceSurgeryFemaleCardiology and Cardiovascular MedicinebusinessPulmonary EmbolismIloprostmedicine.drugThe Annals of thoracic surgery
researchProduct

Healthcare costs of the SATisfaction and adherence to COPD treatment (SAT)study follow-up

2019

Abstract Background Chronic obstructive pulmonary disease (COPD) is characterised by recurring exacerbations. We estimated the costs of healthcare resources for COPD management funded by the Italian National Healthcare Service (INHS) for one year. Methods We examined the demographic, clinical, and economic variables at enrolment and follow-up visits (at 6 and 12 months) of COPD patients participating in the SAT study and referred to 20 Italian pulmonary centres with different institutional characteristics. Costs were expressed in Euro (€) 2018. A random effects log-linear panel regression model was performed to predict the average cost per patient. Results Most of the centres were public in…

Pulmonary and Respiratory MedicineAdultmedicine.medical_specialtyCost-Benefit AnalysisSocio-culturaleMuscarinic AntagonistsPersonal SatisfactionSettore MED/10 - Malattie Dell'Apparato Respiratorio03 medical and health sciencesPulmonary Disease Chronic Obstructive0302 clinical medicineHealth careMedicineHumansCOPD management Econometric model Healthcare costs030212 general & internal medicineAdrenergic beta-2 Receptor AgonistsAverage costAgedAged 80 and overCOPDbiologyCOPD management; Econometric model; Healthcare costsbusiness.industryCOPD managementOxygen Inhalation TherapyRegression analysisHealth Care CostsLamaMiddle AgedHealthcare costsbiology.organism_classificationmedicine.diseaseRandom effects modelBronchodilator AgentsPatient Care ManagementRespiratory Function TestsEconometric model030228 respiratory systemItalyEmergency medicinePublic universityDisease ProgressionPatient ComplianceDrug Therapy CombinationbusinessPanel dataFollow-Up Studies
researchProduct